Skip to content

Study · Case report or series · n = 1 · 2024

3 results

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide.

Bracha P, Johnson W, Chu S, Davison J

American journal of ophthalmology case reports26 Jul 2024Cited by 2 (Europe PMC)

PMID39175932 (opens in a new tab)PMCIDPMC11338990 (opens in a new tab)DOI10.1016/j.ajoc.2024.102121 (opens in a new tab)PepBankPUB-39175932
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 72-year-old man who took oral semaglutide for weight loss, a small central scotoma appeared in the right eye after seventeen days and a similar one later in the left eye, only under scotopic conditions.

    In plain wordsIn one 72-year-old man taking oral semaglutide, blind spots in both eyes appeared in dim light only.

    Peptide
    Semaglutide
    Outcome
    Not applicableBilateral central scotoma under scotopic conditions
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    3.0 mg daily · oralAs given in this study (human).

    Source sentences

    Summary
    A 72-year-old male ophthalmologist (JAD) started 3.0 mg daily oral semaglutide (Rybelsus) to help with weight loss and seventeen days after treatment initiation developed a small, round central scotoma in his right eye that enlarged over several days.
    2 context sentences
    Summary · context
    After two days a similar but smaller scotoma developed in his left eye.
    Summary · context
    These symptoms were present only under scotopic conditions and were not visible in daylight or artificially lit conditions.
  2. 02HumanCase report or seriesSafety outcome

    In this patient, all visual symptoms resolved completely two days after oral semaglutide was stopped.

    In plain wordsIn this one man, the blind spots went away two days after he stopped oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseSymptom resolution after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    3.0 mg daily · oralAs given in this study (human).

    Source sentences

    Summary
    When symptoms developed in the left eye, the medication was discontinued, and all symptoms completely resolved two days later.
  3. 03HumanCase report or seriesSafety outcome

    In this patient, macular optical coherence tomography, fundus photography, fundus autofluorescence and Humphrey visual field showed no abnormalities.

    In plain wordsIn this one man, eye scans and visual field tests after the event showed no abnormalities.

    Peptide
    Semaglutide
    Outcome
    No significant changeOphthalmic examination findings
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    3.0 mg daily · oralAs given in this study (human).

    Source sentences

    Summary
    A subsequent clinical evaluation revealed no abnormalities on macular optical coherence tomography, fundus photography, fundus autofluorescence or Humphrey visual field.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.